Lonza Group (BMV:LONN N) - Stock Price, News & Analysis

LONN N Stock Overview

Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. More details

LONN N fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	1/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 38.7% below our estimate of its fair value

Earnings are forecast to grow 23.9% per year

Analysts in good agreement that stock price will rise by 22.2%

Risk Analysis

Shares are highly illiquid

Profit margins (8.6%) are lower than last year (17.9%)

Large one-off items impacting financial results

Lonza Group AG Competitors

IQVIA Holdings

NYSE:IQV

US$35.3b

Agilent Technologies

NYSE:A

US$36.9b

Mettler-Toledo International

NYSE:MTD

US$24.6b

West Pharmaceutical Services

NYSE:WST

US$22.6b

Price History & Performance

Summary of all time highs, changes and price drops for Lonza Group
Historical stock prices
Current Share Price	CHF 12,817.86
52 Week High	CHF 12,817.86
52 Week Low	CHF 7,382.91
Beta	0.64
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-6.70%

Recent updates

Shareholder Returns

	LONN N	MX Life Sciences	MX Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how LONN N performed against the MX Life Sciences industry.

Return vs Market: Insufficient data to determine how LONN N performed against the MX Market.

Price Volatility

Is LONN N's price volatile compared to industry and market?
LONN N volatility
LONN N Average Weekly Movement	n/a
Life Sciences Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: LONN N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine LONN N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1897	17,834	Wolfgang Wienand	www.lonza.com

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.

Lonza Group AG Fundamentals Summary

How do Lonza Group's earnings and revenue compare to its market cap?
LONN N fundamental statistics
Market cap	Mex$858.38b
Earnings (TTM)	Mex$13.17b
Revenue (TTM)	Mex$153.93b

65.2x

P/E Ratio

5.6x

P/S Ratio

Is LONN N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LONN N income statement (TTM)
Revenue	CHF 6.70b
Cost of Revenue	CHF 4.29b
Gross Profit	CHF 2.41b
Other Expenses	CHF 1.84b
Earnings	CHF 573.00m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Jan 29, 2025

Earnings per share (EPS)	7.93
Gross Margin	36.01%
Net Profit Margin	8.56%
Debt/Equity Ratio	40.3%

How did LONN N perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

50%

Payout Ratio

LONN N Stock Overview

Rewards

Risk Analysis

Lonza Group AG Competitors

NYSE:IQV

US$35.3b

NYSE:A

US$36.9b

NYSE:MTD

US$24.6b

NYSE:WST

US$22.6b

Price History & Performance

Recent News & Updates

Lonza Group AG to Report First Half, 2025 Results on Jul 23, 2025

Lonza Group AG Provides Earnings Guidance for Full Year 2024

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Lonza Group AG to Report Fiscal Year 2024 Results on Jan 30, 2025

Lonza Group AG Approves Cash Dividend, Payable on May 15, 2024

Dividend of CHF2.00 announced

Recent updates

Lonza Group AG to Report First Half, 2025 Results on Jul 23, 2025

Lonza Group AG Provides Earnings Guidance for Full Year 2024

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Lonza Group AG to Report Fiscal Year 2024 Results on Jan 30, 2025

Lonza Group AG Approves Cash Dividend, Payable on May 15, 2024

Dividend of CHF2.00 announced

Lonza Group AG Announces Chief Executive Officer Changes

Investor sentiment improves as stock rises 17%

Lonza Group AG to Report First Half, 2024 Results on Jul 25, 2024

Full year 2023 earnings released: EPS: CHF8.88 (vs CHF16.37 in FY 2022)

Lonza Group AG to Report Fiscal Year 2023 Results on Jan 26, 2024

Lonza Group AG, Annual General Meeting, May 08, 2024

Investor sentiment deteriorates as stock falls 17%

Lonza Group AG Provides Sales Guidance for the Year 2023

Lonza Group AG Announces CEO Changes

Lonza Group AG (SWX:LONN) acquired Synaffix BV.

Lonza Group AG (SWX:LONN) acquired Synaffix BV.

Lonza Group AG Reiterates Sales Guidance for the Years 2023

Upcoming dividend of CHF3.50 per share at 0.6% yield

Full year 2022 earnings released: EPS: CHF16.37 (vs CHF9.08 in FY 2021)

Lonza Group AG to Report First Half, 2023 Results on Jul 21, 2023

Full year 2022 earnings released: EPS: CHF16.37 (vs CHF9.08 in FY 2021)

Lonza Group AG Provides Earnings Guidance for the Year 2023

Lonza Group AG (SWX:LONN) announces an Equity Buyback for CHF 2,000 million worth of its shares.

Lonza Group AG, Annual General Meeting, May 05, 2023

Investor sentiment deteriorated over the past week

Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division, Effective from November 1, 2022

First half 2022 earnings released: EPS: CHF6.67 (vs CHF3.51 in 1H 2021)

Lonza Group AG Reconfirms Sales Guidance for the Years 2022 and 2024

Lonza Group Announces Management Changes, Effective August 1, 2022

High number of new directors

Insufficient new directors

Sigma-Aldrich Corporation acquired Modular Automated Sampling Technology Platform of Lonza Group AG.

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Lonza Group Ltd. Announces Sales Guidance for the Full-Year 2022

Insufficient new directors

Lonza and Triumvira Immunologics Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform

Lonza Group Ltd Provides Earnings Guidance for the Year 2021

Lonza Group Ltd Approves Dividend, Payable Starting from May 12, 2021

Altimmune, Inc. Expands AdCOVID™ Manufacturing Collaboration with Lonza

NextPharma Technologies Holding Limited signed an agreement to acquire Lonza's Ploermel (FR) and Edinburgh (UK) sites from Lonza Group Ltd (SWX:LONN).

Capricor Collaborates with Lonza for the Development of Cap-1002, Its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal

Aurinia Pharmaceuticals Inc. and Lonza Group Ltd Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates

Lonza and Be The Match BioTherapies Partner to Expand Vein-to-Vein Cell and Gene Therapy Supply Chain Network

Altimmune, Inc. Adds Lonza as a Manufacturing Partner for Supply of AdCOVID its Single-Dose Intranasal Vaccine Candidate for COVID-19

Lonza Group Ltd Announces Management Changes

Lonza Reportedly Starts Disposal of Specialty Ingredients Unit

Shareholder Returns

Price Volatility

About the Company

Lonza Group AG Fundamentals Summary

65.2x

5.6x

Earnings & Revenue

Dividends

0.8%